Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Neoplasms 1Multiple Myeloma 1Lymphoma, Mantle-Cell 1Lymphoma 1Hematologic Neoplasms 1Hematologic Diseases 1Fallopian Tube Neoplasms 1Blood Protein Disorders 1

Interventions

Rituximab 93Cyclophosphamide 72fludarabine phosphate 53Whole-Body Irradiation 43Mycophenolic Acid 40Peripheral Blood Stem Cell Transplantation 39Bortezomib 30Tacrolimus 29Etoposide 29Cyclosporine 28Melphalan 26Filgrastim 26Busulfan 26Methotrexate 24Lenalidomide 23Cytarabine 23ibrutinib 20Vincristine 20Granulocyte Colony-Stimulating Factor 20Antilymphocyte Serum 20Doxorubicin 18Bendamustine Hydrochloride 18Dexamethasone 16Sirolimus 14fludarabine 13Carmustine 13Cord Blood Stem Cell Transplantation 12Calcium Dobesilate 12Radiotherapy 11Prednisone 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma, Mantle-Cell × ricolinostat × Clear all
NCT02091063 2024-08-06

ACY-1215 for Relapsed/Refractory Lymphoid Malignancies

Columbia University

Phase 1/2 Terminated
23 enrolled 6 charts
LymphoidOther hematologic neoplasm

Lymphoma, Hematologic Neoplasms, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡